E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Malignant Melanoma |
Melanoma maligno |
|
E.1.1.1 | Medical condition in easily understood language |
Malignant Melanoma |
M;elanoma maligno |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cancer [C04] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 16.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10025650 |
E.1.2 | Term | Malignant melanoma |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
- To estimate the survival rate at 1 year in adolescent patients (12 to < 18 years) with previously treated or untreated, unresectable Stage III or Stage IV malignant melanoma. - To assess safety and tolerability, specifically the frequency of severe (grade 3 - 5) immune-mediated adverse reactions of ipilimumab in adolescent patients (12 to < 18 years) at the 10 mg/kg dose level. - To comply with the Pediatric Investigation Plan requirements for Ipilimumab |
Estimar la tasa de supervivencia a 1 año en pacientes adolescentes (de 12 a < 18 años) con melanoma maligno en estadio III irresecable o en estadio IV, previamente tratado o no tratado Evaluar la seguridad y tolerabilidad, concretamente la frecuencia de reacciones adversas graves (de grado 3 - 5) mediadas por el sistema inmunitario como consecuencia del tratamiento con ipilimumab en pacientes adolescentes (de 12 a < 18 años) con la dosis de 10 mg/kg |
|
E.2.2 | Secondary objectives of the trial |
Using mWHO criteria: -Disease Control Rate -Progression Free Survival -Best Overall Response Rate -Overall Survival |
Usando criterios de la OMS: -Tasa de control de la enfermedad -Supervivencia libre de proresión -Mejor tasa de respuesta global -Supervivencia Global |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
- 12 < 18 years of age - Previously Treated or Untreated, Unresectable - Stage III or Stage IV Malignant Melanoma KPS or Lansky Score of ? 50 |
Rango de edad de 12 < 18 años de eda - Pacientes con melanoma maligno en estadío III, irresecable o estadío IV previamente tratados o no tratados KPS o Indice de Lansky ? 50 |
|
E.4 | Principal exclusion criteria |
- Primary Ocular Melanoma - Prior therapy with CTLA-4 or PD-1 antagonist, or PD-L1 or CD137 agonists - Symptomatic brain metastases - History of autoimmune disease |
- Melanoma ocular primario - Pacientes con tratamiento previo con CTLA-4 o antagonistas de PD-1, o PD-L1 o agonistas CD137 - Metástasis cerebrales sintomáticas - Historia de enfermedad autoimmune |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Overall Survival at 1 year and Frequency of Severe imARs (grade 3-5) |
supervivencia global a 1 año y frecuencia de reacciones adversas graves nediadas por el sistema inmunitario(imArs) (grado 3-5) |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Day 1 of FPFT to Day 365 from LPFT |
Día 1 del FPFT hasta día 365 desde from LPFT |
|
E.5.2 | Secondary end point(s) |
Using mWHO criteria: -Disease Control Rate -Progression Free Survival -Best Overall Response Rate -Overall Survival |
Usando criterios de la OMS: -Tasa de control de la enfermedad -Supervivencia libre de proresión -Mejor tasa de respuesta global -Supervivencia Global |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Analyses will be performed at the same time as the Primary Analysis |
El análisis se realizará al mismo tiempo que el análisis primario. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | No |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Yes |
E.6.13.1 | Other scope of the trial description |
biomarker assessments, blood samples for anti-drug antibodies (ADA) testing |
Evaluaciones de biomarcador, y del ensayo de anticuerpos anti medicamento en muestars sanguíneas (ADA) |
|
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | Yes |
E.8.1.7.1 | Other trial design description |
|
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 1 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 10 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Australia |
Belgium |
France |
Germany |
Mexico |
United Kingdom |
United States |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
Last visit of the last subject |
Última visita del último paciente |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 4 |
E.8.9.1 | In the Member State concerned months | 6 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 4 |
E.8.9.2 | In all countries concerned by the trial months | 6 |
E.8.9.2 | In all countries concerned by the trial days | 0 |